Analyst spotlights a compelling commercial future ahead for Sorrento’s ZTlido in post-herpetic neuralgia.
Ram Selvaraju slashes his target to $8 on slower Trulance ramp.
Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.
Analyst defends ADXS’ new “astute” clinical development strategy to re-focus on leading product assets.
RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.
H.C.
Analyst Swayampakula Ramakanth of H.C.
Analyst Joseph Pantginis of H.C.
Ocular Therapeutix Inc (NASDAQ:OCUL) shares are on a roughly 4% dip today after the biotech firm released second-quarter financial results- a quarter that …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 IAP312 clinical trial of Zalviso, approved in the …